Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 KisqaliⓇ achieved statistically significant OS benefit in MONALEESA-2 Improvement in median OS was 12.5 months with Kisqali Ⓡ plus letrozole Presented at ESMO 2021 100 80 60 Overall Survival, % 60 40 I 20 20 T Events/n Median OS, mo HR (95% CI) RIB + LET 181/334 63.9 PBO + LET 219/334 51.4 ■ 0.76 (0.63-0.93) P value .004 O 4 8 12 ܘ܂ 16 20 20 - -24 24 28 3 - 32 36 40 40 44 48 52 52 -S 56 60 -80 T -8 - 64 68 72 -2 76 80 60 84 88 Months No. at risk RIB + LET 334 323 315 305 300 284 270 253 237 220 202 191 180 165 158 150 142 PBO+LET 334 326 316 306 293 283 265 244 222 209 195 183 167 149 139 131 114 104 94 73 38 135 125 101 ៨ថ្មី 48 88 8 6 oo 0 0 0 aBC advanced breast cancer 19 Investor Relations | Q3 2021 Results INNOVATION ■ Longest median OS in advanced breast cancer (>5 yrs) Significant survival benefit (>1 yr) ■ + endocrine therapy the only first- line treatment with OS benefit ■ Considered as preferred treatment option for HR+/HER2- ABC Planning to submit this OS data to be incorporated into drug labels NOVARTIS | Reimagining Medicine

View entire presentation